Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders
- MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Intra-Cellular Therapies (Nasdaq: ITCI) for possible breaches of fiduciary duty and other violations of law in its transaction with Johnson & Johnson. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Intra-Cellular Therapies stockholders will receive only $132.00 per share in cash.
- 01/13/2025
|
BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal
- Intra-Cellular +32.49 (+34.25%) Johnson & Johnson +2.22 (+1.56%)
- 01/13/2025
|
ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz
- Intra-Cellular stock gains 15% as it settles Caplyta patent litigation with Sandoz protecting the drug's exclusivity in the United States till July 1, 2040.
- 01/13/2025
|
Drugmakers rush to sign deals on first day of industry conference
- Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
- 01/13/2025
|
Intra-Cellular just downgraded at Morgan Stanley, here's why
- Intra-Cellular +32.2 (+33.94%) Johnson & Johnson +1.38 (+0.97%)
- 01/13/2025
|
Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B
- Shares of Intra-Cellular Therapies (ITCI) are surging 35% in premarket trading Monday after Johnson & Johnson (JNJ) said it will acquire the biopharmaceutical company for roughly $14.6 billion.
- 01/13/2025
|
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-Cellular Therapies, Inc. Is Fair to Shareholders
- NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share in cash is fair to Intra-Cellular shareholders. Halper Sadeh encourages Intra-Cellular shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation.
- 01/13/2025
|
Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains?
- Intra-Cellular (ITCI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 01/13/2025
|
J&J to buy Intra-Cellular Therapies for $14.6 billion
- Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its presence in the market for neurological disorder treatments.
- 01/13/2025
|
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
- Acquisition includes CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults
- 01/13/2025
|
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
- NEW BRUNSWICK, N.J. & BEDMINSTER, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $132.00 per share in cash for a total equity value.
- 01/13/2025
|
Johnson & Johnson eyes $10bn acquisition of Intra-Cellular Therapies
- Johnson & Johnson (NYSE:JNJ) is reportedly in talks to acquire neuroscience-focused biotech firm Intra-Cellular Therapies for $10bn. If completed, the deal would mark the largest biotech acquisition since Pfizer's $43bn purchase of Seagen in 2023.
- 01/13/2025
|
J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports
- Johnson & Johnson is exploring a bid to acquire Intra-Cellular Therapies Inc , a biopharmaceutical company, Bloomberg News reported on Sunday citing people familiar with the matter.
- 01/12/2025
|
Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz
- BEDMINSTER, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Sandoz Inc. (Sandoz) resolving patent litigation related to Intra-Cellular Therapies' product CAPLYTA® (lumateperone). The litigation, which is pending in the U.S. District Court for the District of New Jersey, resulted from submission by Sandoz of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic equivalent of CAPLYTA in the United States. The settlement agreement permits Sandoz to begin selling generic versions of CAPLYTA on July 1, 2040, or earlier under certain circumstances. As required by law, Intra-Cellular Therapies will submit the agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice. Similar patent litigation brought by Intra-Cellular Therapies against other parties remains pending in the U.S. District Court for the District of New Jersey.
- 01/10/2025
|
Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- BEDMINSTER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT in San Francisco, CA.
- 01/06/2025
|
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting
- Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder
- 12/11/2024
|
Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move
- CAPLYTA showed strong revenue growth, with Q3 2024 net product revenues of $125.8 million, which was a 39% year-over-year increase. Potential revenue boost if CAPLYTA's label is expanded to include it as an adjunctive therapy for major depressive disorder, addressing a significant unmet need. Lenrispodun, a PDE inhibitor, is in a phase 2 study for Parkinson's Disease, with potential data release by late 2025/early 2026, offering another blockbuster opportunity.
- 12/08/2024
|
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
- Intra-Cellular submits an sNDA to the FDA, seeking the label expansion of Caplyta to treat MDD in adults as an adjunctive therapy to antidepressants.
- 12/04/2024
|
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
- BEDMINSTER, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced that it has recently submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for CAPLYTA (lumateperone) for the treatment of Major Depressive Disorder (MDD) in adults, as adjunctive therapy to antidepressants.
- 12/03/2024
|
Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?
- Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
- 11/29/2024
|
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
- BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:
- 11/19/2024
|
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
- Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
- 11/07/2024
|
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial
- Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.
- 11/05/2024
|
Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder, Chairman and CEO Mark Neumann - EVP and CCO Sanjeev Narula - CFO Suresh Durgam - EVP and CMO Conference Call Participants Andrew Tsai - Jefferies Jessica Fye - JPMorgan Charles Duncan - Cantor Jason Gerberry - Bank of America Securities Jeff Hung - Morgan Stanley Michael DiFiore - Evercore David Amsellem - Piper Sandler Joel Beatty - Baird Corinne Johnson - Goldman Sachs Operator Good day and thank you for standing by. Welcome to Intra-Cellular Therapies 3Q 2024 Earnings Conference Call.
- 10/30/2024
|
ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
- Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
- 10/30/2024
|
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
- Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.25 per share a year ago.
- 10/30/2024
|
Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
- CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase
- 10/30/2024
|
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
- Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/23/2024
|
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
- NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, October 30, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2024.
- 10/17/2024
|
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
- ITCI is seeing strong Caplyta sales, driven by a high prescription rate. However, its heavy reliance on the drug's sales for growth is concerning.
- 10/11/2024
|
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
- Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
- 09/23/2024
|
Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
- Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
- 09/06/2024
|
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
- NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:
- 08/28/2024
|
Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon
- This biotech stock is in a base and seeking support at a moving average. The company's losses are dwindling and analysts see profits coming.
- 08/08/2024
|
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
- Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
- 08/08/2024
|
Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
- NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 12:00 p.m. ET in Boston, MA.
- 08/08/2024
|
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
- Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.45 per share a year ago.
- 08/07/2024
|
Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
- NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sanjeev Narula will join the Company on August 12, 2024 and will serve as Executive Vice President, Chief Financial Officer. Mr. Narula will report to Dr. Sharon Mates, ITCI's Chairman and Chief Executive Officer. Lawrence Hineline, who currently serves as Chief Financial Officer, will retire on the same date but will continue to serve as a consultant to the Company for a period of time to ensure a smooth transition.
- 08/07/2024
|
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
- CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a 46% increase
- 08/07/2024
|
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/31/2024
|
Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
- NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, August 7, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended June 30, 2024.
- 07/24/2024
|
Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?
- The average of price targets set by Wall Street analysts indicates a potential upside of 30.1% in Intra-Cellular (ITCI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 07/09/2024
|
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
- Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
- 06/24/2024
|
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
- Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
- 06/19/2024
|
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
- Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 06/19/2024
|
Intra-Cellular Brightens MDD Outlook With Caplyta Success
- Caplyta (lumateperone) shows significant promise as an adjunctive treatment for Major Depressive Disorder. Caplyta's unique pharmacological profile targeting serotonin, dopamine, and glutamate pathways sets it apart in the saturated MDD market. Intra-Cellular's financial stability is supported by strong sales growth and sufficient cash reserves to sustain operations until 2027.
- 06/19/2024
|
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
- Tuesday, Intra-Cellular Therapies Inc ITCI released topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).
- 06/18/2024
|
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
- In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
- 06/18/2024
|
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
- NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 45th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2024 at 10:00 a.m. ET in Miami, FL.
- 06/10/2024
|
Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report?
- Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
- 06/06/2024
|
The Secret Stock Stash: 3 Overlooked Picks That Belong in Every Portfolio
- While it's always comforting to bank on ideas that the masses believe in, overlooked stocks have their charm too. By targeting enterprises that relatively few investors follow, should the stars align just right, the rewards could be enormous.
- 05/30/2024
|
Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference
- NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET in New York, NY.
- 05/29/2024
|
Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
- NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today highlights data presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held in Miami, May 28 - 31, 2024.
- 05/23/2024
|
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
- Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
- 05/08/2024
|
Intra-Cellular Therapies, Inc. (ITCI) Q1 2024 Earnings Call Transcript
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Juan Sanchez - Vice President of Corporate Communications and Investor Relations Sharon Mates - Founder, Chairman and Chief Executive Officer Mark Neumann - Executive Vice President and Chief Commercial Officer Lawrence Hineline - Senior Vice President of Finance and Chief Financial Officer Suresh Durgam - Executive Vice President and Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Brian Abrahams - RBC Capital Markets Andrew Tsai - Jefferies Charles Duncan - Cantor Fitzgerald Marc Goodman - Leerink Partners Michael DiFiore - Evercore ISI Jason Gerberry - Bank of America Securities Sumant Kulkarni - Canaccord Genuity Michael Riad - Morgan Stanley Charles Wang - Mizuho Securities Troy Langford - TD Cowen Ashwani Verma - UBS Ami Fadia - Needham Corinne Johnson - Goldman Sachs David Amsellem - Piper Sandler Joel Beatty - Baird Operator Good morning, ladies and gentlemen, and welcome to Intra-Cellular Therapies' First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 05/07/2024
|
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
- Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.46 per share a year ago.
- 05/07/2024
|
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
- CAPLYTA Q1 2024 net product sales were $144.8 million , compared to $94.7 million for the same period in 2023 , representing a 53% increase
- 05/07/2024
|
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
- NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, May 7, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2024.
- 04/30/2024
|
Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy
- The share price reaction of Intra-Cellular Therapies was not as strong as expected after the positive phase 3 results of Caplyta in major depressive disorder. Positive MDD results represent another de-risking event for the drug and should open up another large market for Caplyta, pending positive results from the second phase 3 trial. The company's commercial momentum remains strong, with strong sequential and YoY growth in the first quarter.
- 04/30/2024
|
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
- Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/25/2024
|
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
- NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has completed the sale of an additional 1,027,397 shares of its common stock at a public offering price of $73.00 per share on April 24, 2024, pursuant to the full exercise of the option granted by Intra-Cellular Therapies to the underwriters in connection with its previously announced public offering of 6,849,316 shares of common stock, which closed on April 22, 2024.
- 04/24/2024
|
3 Biotech Stocks With Skyrocketing Potential: April 2024
- Investing in biotech stocks is not for the faint of heart. The sector is prone to wild swings in stock prices, offering a distinctive blend of high risk and high reward.
- 04/24/2024
|
Intra-Cellular Therapies Prices Public Offering of Common Stock
- NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $500.0 million before deducting underwriting discounts and commissions and offering expenses. Intra-Cellular Therapies has granted the underwriters a 30-day option to purchase up to an additional 1,027,397 shares on the same terms and conditions. The offering is expected to close on April 22, 2024, subject to the satisfaction of customary closing conditions.
- 04/17/2024
|
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
- Intra-Cellular (ITCI) jumps 23% after achieving key goals in the late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
- 04/17/2024
|
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
- Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 04/17/2024
|
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
- NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering will be sold by Intra-Cellular Therapies.
- 04/16/2024
|
Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
- Intra-Cellular Therapies, Inc. achieved positive results from Study 501, using lumateperone as an adjunctive therapy for the treatment of patients with MDD; Both primary and secondary endpoints achieved with statistical significance.
- 04/16/2024
|
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
- Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
- 04/16/2024
|
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
- NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the promotion of Michael Halstead, J.D. to the position of President. Mr. Halstead is currently serving as Executive Vice President and General Counsel. In this newly created leadership role, Mr. Halstead will oversee several functions within the Company including legal, human resources, manufacturing & supply chain, quality, compliance, information technology, and external innovation. He will continue to report to Dr. Sharon Mates, Chairman and Chief Executive Officer.
- 03/19/2024
|
Intra-Cellular Therapies Is On Fire
- Intra-Cellular Therapies' flagship drug, CAPLYTA, saw a 63% increase in the number of psychiatrists prescribing it in 2023. The company is seeking FDA approval to expand CAPLYTA's use to treat Major Depressive Disorder. CAPLYTA's growing acceptance contributed to a 50% YoY increase in revenue for Intra-Cellular Therapies in Q4 2023.
- 03/11/2024
|
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
- NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in three upcoming investor conferences:
- 03/06/2024
|
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference
- NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 11:10 a.m. ET in Boston, MA.
- 02/27/2024
|
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
- Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.
- 02/23/2024
|
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
- Now that the FED is looking to lower interest rates this year, cheaper money and more accessible financing will let investors venture into riskier places in the economy and the stock market. While not that risky of an industry, the biotech space can often be speculative.
- 02/21/2024
|
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
- Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.
- 02/21/2024
|
Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
- Intra-Cellular's share price has increased by 450% over a five-year period and over 50% in the past year. The company's success is attributed to its approved drug, Caplyta, which has driven significant revenue growth. Intra-Cellular is running Phase 3 studies to expand Caplyta's label into major depressive disorder, presenting a potential future growth opportunity.
- 02/10/2024
|
Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 8:15 a.m. PT in San Francisco, CA.
- 01/02/2024
|
3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
- The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a challenging year, there have been some winners in the biotech sector - I have been fortunate to share a few successful tips with Seeking Alpha readers.
- 12/29/2023
|
Intra-Cellular Therapies (ITCI) is a Great Momentum Stock: Should You Buy?
- Does Intra-Cellular Therapies (ITCI) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 12/19/2023
|
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
- Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
- 12/18/2023
|
The Right Play On Intra-Cellular Therapies
- Intra-Cellular Therapies, Inc. is a mid-cap biopharmaceutical company focused on developing treatments for neuropsychiatric and neurological disorders. The company's commercial asset, Caplyta, has achieved significant sales growth and is an exciting entry in the antipsychotic market. Intra-Cellular is also evaluating the potential of Caplyta for other indications and has several other early-to-mid stage clinical programs in its pipeline.
- 11/20/2023
|
Intra-Cellular's Caplyta Is Well On Its Way To Being A Mental Health Blockbuster
- Intra-Cellular Therapies shows strong financial growth, driven by Caplyta sales, with improved operational efficiency and reduced net losses. Caplyta's success in schizophrenia and bipolar depression, and its potential in Major Depressive Disorder, underscore its clinical promise. Financial health is solid with a good cash runway; market dynamics are mixed, with high institutional ownership but insider selling.
- 11/13/2023
|
Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised
- Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue to drive growth.
- 11/03/2023
|
Intra-Cellular Therapies, Inc. (ITCI) Q3 2023 Earnings Call Transcript
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Juan Sanchez – Head-Investor Relations Sharon Mates – Chairman and Chief Executive Officer Mark Neumann – Chief Commercial Officer Larry Hineline – Chief Financial Officer Suresh Durgam – Chief Medical Officer Conference Call Participants Tanmay Patwardhan – J.P. Morgan Andrew Tsai – Jefferies Charles Duncan – Cantor Fitzgerald Umer Raffat – Evercore Michael Riad – Morgan Stanley Marc Goodman – Leerink Ami Fadia – Needham & Company Graig Suvannavejh – Mizuho Securities Jason Gerberry – Bank of America Corinne Jenkins – Goldman Sachs Operator Thank you for standing by, and welcome to the Intra-Cellular Therapies 3Q 2023 Earnings Conference Call.
- 11/02/2023
|
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
- NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in two upcoming investor conferences:
- 10/31/2023
|
Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
- NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023 at 1:15 p.m. ET.
- 09/20/2023
|
Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
- NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023 at 12:55 p.m. ET.
- 09/05/2023
|
Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline
- Intra-Cellular Therapies' main drug, Caplyta, has been successful in treating neuropsychiatric conditions and has shown potential in addressing mixed features in mood disorders. Q2 2023 earnings report showed substantial revenue growth driven by Caplyta's net product sales, although the company still recorded a net loss. The company's growth initiatives include exploring the potential of lumateperone in Major Depressive Disorder, developing new formulations, and expanding their pipeline with new programs.
- 08/12/2023
|
Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised
- Intra-Cellular (ITCI) reports better-than-expected second-quarter results. Caplyta sales continue to drive growth.
- 08/04/2023
|
Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference
- NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 at 1:30 p.m. ET.
- 08/04/2023
|
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
- Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.92 per share a year ago.
- 08/03/2023
|
Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast
- NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, August 3, 2023, to provide a corporate update and discuss details of the Company's financial results for the quarter ended June 30, 2023.
- 07/28/2023
|
Intra-Cellular Therapies: Depression Data Boosts Investment Prospects (Rating Upgrade)
- Intra-Cellular's drug Caplyta (lumateperone) is advancing through trials for major depressive disorder (MDD), expanding its approved uses beyond schizophrenia and bipolar depression. Caplyta faces exclusivity expiration in December 2024, compelling Intra-Cellular to rely on Orange Book patents and promising pipeline candidates.
- 05/25/2023
|
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
- NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at two upcoming investor conferences:
- 05/02/2023
|
Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast
- NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, May 4, 2023, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2023.
- 04/26/2023
|
Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe
- Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.
- 04/21/2023
|
Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?
- Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
- 03/31/2023
|
Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up
- Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.
- 03/29/2023
|
Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?
- Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 03/29/2023
|
Why Intra-Cellular Therapies Climbed Tuesday
- Caplyta, the company's lead drug, was responsible for most of the company's revenue in 2022. The potential addition of major depressive disorder to the indications Caplyta treats would significantly increase the drug's potential patient population.
- 03/28/2023
|
Intra-Cellular's Big Depression Drug Market Just Got Bigger — And Shares Catapulted
- Intra-Cellular said Tuesday its depression treatment succeeded in a key study, and ITCI stock broke definitively above its 200-day line. The post Intra-Cellular's Big Depression Drug Market Just Got Bigger — And Shares Catapulted appeared first on Investor's Business Daily.
- 03/28/2023
|
Intra-Cellular's stock jumps on new data for depression drug
- Shares of Intra-Cellular Therapies Inc. ITCI, +2.46% jumped about 15% in premarket trading on Tuesday after the company said its experimental treatment for major depressive disorder met the primary endpoint in a Phase 3 clinical trial. The drug, lumateperone, is being tested as a treatment for episodes associated with major depressive disorder and bipolar depression with fixed features, which are manic symptoms.
- 03/28/2023
|
Intra-Cellular (ITCI) Q4 Earnings & Sales Top, Caplyta Shines
- Intra-Cellular Therapeutics (ITCI) reports a better-than-expected financial performance in the fourth quarter of 2022 as both earnings and revenues beat estimates.
- 03/02/2023
|
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
- Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 5.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2023
|
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast
- NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, March 1, 2023, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2022.
- 02/14/2023
|
Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference
- NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:40 a.m. ET.
- 02/08/2023
|
Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conference
- NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. PT.
- 01/03/2023
|
Has IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year?
- Here is how Intra-Cellular Therapies (ITCI) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.
- 12/22/2022
|
Intra-Cellular: Hitting A Growth Inflection (Rating Upgrade)
- Following approval for schizophrenia in late 2019, Caplyta then gained its first label expansion for bipolar depression. As Caplyta is serving a much larger market, sales growth has hit an inflection point in the following year.
- 12/18/2022
|
Can Intra-Cellular (ITCI) Climb 33% to Reach the Level Wall Street Analysts Expect?
- The consensus price target hints at a 32.7% upside potential for Intra-Cellular (ITCI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 11/23/2022
|
Intra-Cellular's (ITCI) Caplyta Aids Growth, Overdependence a Woe
- Intra-Cellular Therapeutics (ITCI) currently has only one marketed product in its portfolio, Caplyta, approved for schizophrenia and bipolar disorders. The company is evaluating the candidate in several other indications.
- 11/18/2022
|
How Much Upside is Left in Intra-Cellular (ITCI)? Wall Street Analysts Think 33%
- The consensus price target hints at a 33.5% upside potential for Intra-Cellular (ITCI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 11/07/2022
|
Intra-Cellular Therapies, Inc. (ITCI) Q3 2022 Earnings Call Transcript
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Co-Founder, Chairman, CEO & President Mark Neumann - EVP & Chief Commercial Officer Lawrence Hineline - SVP, Finance, CFO, Treasurer & Assistant Secretary Suresh Durgam - EVP & Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Brian Abrahams - RBC Capital Markets Michael DiFiore - Evercore ISI Ami Fadia - Needham & Company Ashwani Verma - UBS David Amsellem - Piper Sandler & Co. Marc Goodman - SVB Securities Graig Suvannavejh - Mizuho Securities Charles Duncan - Cantor Fitzgerald Operator Good morning, ladies and gentlemen, and welcome to intracellular Therapies Third Quarter Earnings Call. At this time, all participants are in a listen-only mode.
- 11/03/2022
|
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
- Intra-Cellular (ITCI) delivered earnings and revenue surprises of 33.72% and 10.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2022
|
Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now
- Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.
- 10/17/2022
|
Intra-Cellular Therapies: What Lies Ahead
- Today, we circle back on mid-cap biopharma name Intra-Cellular Therapies, Inc. for the first time since 2020. Intra-Cellular Therapies' flagship product CAPLYTA (lumateperone) has significant potential across multiple indications including to treat bipolar disorder and schizophrenia.
- 09/20/2022
|
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q2 2022 Results - Earnings Call Transcript
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Juan Sanchez - Vice President, Corporate Communications and Investor Relations Sharon Mates - Chairman and Chief Executive Officer Mark Neumann - Executive Vice President and Chief Commercial Officer Suresh Durgam - Executive Vice President Chief Medical Officer Larry Hineline - Senior Vice President and Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Jessica Fye - JPMorgan Mike DiFiore - Evercore Brian Abrahams - RBC Capital Markets Charles Duncan - Cantor Fitzgerald Marc Goodman - SVB Karin Jenkins - Goldman Sachs Jason Gerberry - Bank of America Ash Verma - UBS Sumant Kulkarni - Canaccord Operator Good morning, ladies and gentlemen, and welcome to the Intra-Cellular Therapies' Second Quarter Earnings Call. At this time, all participants on a listen-only mode.
- 08/09/2022
|
Intra-Cellular Therapies to Host Second Quarter 2022 Financial Results Conference Call and Webcast
- NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, August 9, 2022, to provide a corporate update and discuss details of the Company's financial results for the quarter ended June 30, 2022.
- 08/02/2022
|
What Stocks To Buy This Week? 4 Biotech Stocks To Know
- Should investors pay more attention to these biotech stocks?
- 05/15/2022
|
Why Intra-Cellular Therapies Stock Rose 21.4% This Week
- Strong sales for the company's only marketed therapy piqued investors' interest.
- 05/12/2022
|
Why Intra-Cellular Therapies Trounced the S&P 500 Today
- The biotech notches an extremely convincing first-quarter earnings beat.
- 05/10/2022
|
Robust Uptake Of Antipsychotic Drug Boosts Intra-Cellular's Q1 Earnings
- Intra-Cellular Therapies Inc's (NASDAQ: ITCI) Q1 revenues reached $35.0 million, compared to $15.9 million a year ago, beating the consensus of $33.65 million. Net product revenues of Caplyta were $34.8 million, compared to $15.6 million in Q1 FY21.
- 05/10/2022
|
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q1 2022 Results - Earnings Call Transcript
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Juan Sanchez - Vice President, Corporate Communications and Investor Relations Sharon Mates - Chairman and Chief Executive Officer Mark Neumann - Executive Vice President and Chief Commercial Officer Suresh Durgam - Executive Vice President Chief Medical Officer Larry Hineline - Senior Vice President and Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Jessica Fye - JP Morgan Charles Duncan - Cantor Fitzgerald Brian Abrahams - RBC Capital Markets Mike DiFiore - Evercore Marc Goodman - SVB Securities Sumant Kulkarni - Canaccord Jason Gerberry - Bank of America Karin Jenkins - Goldman Sachs David Amsellem - Piper Sandler Operator Good morning, ladies and gentlemen. And welcome to Intra-Cellular Therapies First Quarter Earnings Call.
- 05/10/2022
|
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
- Intra-Cellular (ITCI) delivered earnings and revenue surprises of 16.13% and 5.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/10/2022
|
Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand
- CAPLYTA has been approved by the FDA for the treatment of adults with schizophrenia and adults with bipolar depression.
- 03/08/2022
|
Intra-Cellular Therapies' (ITCI) CEO Sharon Mates on Q4 2021 Results - Earnings Call Transcript
- Intra-Cellular Therapies' (ITCI) CEO Sharon Mates on Q4 2021 Results - Earnings Call Transcript
- 03/01/2022
|
Why Earnings Season Could Be Great for Intra-Cellular Therapies (ITCI)
- Intra-Cellular Therapies (ITCI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/28/2022
|
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast
- NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, March 1, 2022, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2021.
- 02/22/2022
|
Intra-Cellular Therapies to Present at the 11th Annual SVB Leerink Global Healthcare Conference
- NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 8:40 am ET.
- 02/10/2022
|
12 biotech stocks to consider buying now as prospects for the sector brighten this year
- Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double
- 02/06/2022
|
Diversify Your Portfolio With a New Psychedelic Drug ETF
- A new thematic ETF providing exposure to the medicinal psychedelic drug industry, PSYK ETF, has just been launched.
- 02/02/2022
|
Strength Seen in Intra-Cellular (ITCI): Can Its 9.8% Jump Turn into More Strength?
- Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 01/24/2022
|
Why Intra-Cellular Therapies Took a Big Hit Today
- The company is floating at least $400 million worth of its common stock.
- 01/04/2022
|
IntraCellular Seeks To Raise $400M Via Equity To Fund Commercialization Of Schizophrenia Med
- Intra-Cellular Therapies Inc (NASDAQ: ITCI) commenced an underwritten public offering of $400 million of shares. Underwriters have an option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
- 01/04/2022
|
Intra-Cellular: Unlocking Value With FDA Approval
- Intra-Cellular Therapies is rewarding shareholders while bringing stellar medicine to patients suffering from psychiatric conditions. As a differentiated neuroleptic, Caplyta demonstrated robust efficacy with minimal side effects.
- 12/23/2021
|
Intra-Cellular's Second FDA Win Makes It A Great Long-Term Investment
- Intra-Cellular Therapies received FDA approval of CAPLYTA for the treatment of adults with bipolar depression. Total revenues of CAPLYTA in Q3 2021 for treatment of adults with Schizophrenia surged by 200% to $22.1 million compared to the same time period in the prior year.
- 12/21/2021
|
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q3 2021 Results - Earnings Call Transcript
- Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q3 2021 Results - Earnings Call Transcript
- 11/09/2021
|
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
- Intra-Cellular (ITCI) delivered earnings and revenue surprises of -6.74% and 1.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/09/2021
|
Intra-Cellular Therapies: Q3 Earnings Insights
- Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
- 11/09/2021
|
Intra-Cellular Therapies to Host Third Quarter 2021 Financial Results Conference Call and Webcast
- NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, November 9, 2021, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2021.
- 11/02/2021
|
Intra-Cellular Therapies to Host a Virtual Event to Feature Highlights of Several of its Development Programs
- Virtual event to include discussions on our lumateperone, ITI-1284, PDE1 inhibitors and ITI-333 platforms
- 10/08/2021
|
Intra-Cellular says clinical study shows its schizophrenia drug helps patients with bipolar disorder
- Shares of Intra-Cellular Therapies Inc. ITCI, -1.12% gained 1.5% in premarket trading on Monday after the company said clinical data showed that its experimental treatment for bipolar disorder reduced depressive symptoms. The Phase 3 study evaluated Caplyta, which is already approved as a treatment for schizophrenia, in 381 people with bipolar I or bipolar II disorder who were experiencing a depressive episode.
- 09/27/2021
|
Intra-Cellular Therapies Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry
- In this study, lumateperone 42 mg showed significant reduction in depressive symptoms compared to placebo in patients with a major depressive episode associated with bipolar I or bipolar II disorder and a favorable safety and tolerability profile. These anti-depressant effects were statistically significant in both bipolar I and bipolar II disorder subgroup populations
- 09/27/2021
|
Intra-Cellular Therapies Announces Publications Highlighting Beneficial Effects of Phosphodiesterase Type I Inhibition with Lenrispodun (ITI-214) on Cardiovascular Function in Patients with Heart Failure and in Models of Accelerated Aging
- Results of Study ITI-214-104 show that lenrispodun, in a Phase 1/2a Study, is well tolerated and acts as an inodilator in patients with heart failure without inducing abnormal heart rhythms (Circulation: Heart Failure; Gilotra, et al, 2021)
- 09/20/2021
|
Why Intra-Cellular Therapies Was Weak This Week
- The company's second-quarter net loss was a bit deeper than analysts expected.
- 08/13/2021
|
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q2 2021 Results - Earnings Call Transcript
- Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q2 2021 Results - Earnings Call Transcript
- 08/09/2021
|
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
- Intra-Cellular (ITCI) delivered earnings and revenue surprises of -7.59% and 8.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2021
|
Intra-Cellular Therapies: Q2 Earnings Insights
- Shares of Intra-Cellular Therapies (NASDAQ:ITCI) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share rose 11.46% over the past year to ($0.85), which missed the estimate of ($0.80).
- 08/09/2021
|
Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021.
- 08/09/2021
|
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment
- Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.
- 06/02/2021
|
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q1 2021 Results - Earnings Call Transcript
- Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q1 2021 Results - Earnings Call Transcript
- 05/10/2021
|
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
- Intra-Cellular (ITCI) delivered earnings and revenue surprises of 19.75% and 0.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/10/2021
|
Recap: Intra-Cellular Therapies Q1 Earnings
- Shares of Intra-Cellular Therapies (NASDAQ:ITCI) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share rose 10.96% over the past year to ($0.65), which beat the estimate of ($0.80).
- 05/10/2021
|
Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
- CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression in adults as both monotherapy and adjunctive treatment with lithium or valproate have been accepted for review by the FDA, with a PDUFA target action date of December 17, 2021.
- 05/10/2021
|
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
- NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Applications (sNDAs) for lumateperone, an investigational agent for the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 17, 2021 for the applications. If approved, CAPLYTA has the potential to be an important medicine for a broad group of patients suffering from these highly prevalent, chronic complex conditions.
- 05/03/2021
|
Intra-Cellular: Substantial Unlocked Value In Caplyta Franchises
- After its recent launch of Caplyta for schizophrenia, Intra-Cellular Therapies is poised to gain Caplyta label expansion for bipolar depression. Aside from three label expansions for Caplyta, the company is innovating other forms of Caplyta.
- 04/23/2021
|
Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting
- Webcast to be Held Tuesday, May 4, 2021 at 2:00 p.m. EDT
- 04/22/2021
|
Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting
- Board of Directors Nominates Sir Michael Rawlins GBE M.D., FRCP, FMedSci, Former Chairman of the UK's Medicines and Healthcare products Regulatory Agency (MHRA), as a New, Independent Director Board of Directors Nominates Sir Michael Rawlins GBE M.D., FRCP, FMedSci, Former Chairman of the UK's Medicines and Healthcare products Regulatory Agency (MHRA), as a New, Independent Director
- 04/20/2021
|
Intra-Cellular: Label Expansion PDUFA Up Ahead
- ITCI has one approved product targeting schizophrenia patients. It has an sNDA filed for a larger indication.
- 03/28/2021
|
Intra-Cellular Therapies, Inc.'s (ITCI) CEO Sharon Mates on Q4 2020 Results - Earnings Call Transcript
- Intra-Cellular Therapies, Inc.'s (ITCI) CEO Sharon Mates on Q4 2020 Results - Earnings Call Transcript
- 02/25/2021
|
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update
- Successfully launched CAPLYTA ® (lumateperone) in late March 2020 and demonstrated strong commercial execution in the midst of COVID-19.
- 02/25/2021
|
Intra-Cellular Therapies Discloses New Drug Candidate For Dementia Related Episodes
- Intra-Cellular Therapies Inc (NASDAQ: ITCI) expands its pipeline with a new molecular entity, ITI-1284, a sublingually delivered deuterated form of lumateperone. ITI-1284 has been developed in collaboration with Catalent Inc (NYSE: CTLT), using its proprietary Zydis ODT (orally disintegrating tablet) fast-dissolving formulation.
- 02/24/2021
|
Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284
- ITI-1284 is a deuterated form of lumateperone delivered sublingually as an orally disintegrating tablet (ODT-SL). ITI-1284 ODT-SL may offer pharmacologic benefits and ease-of-use for patients, particularly in elderly populations.
- 02/24/2021
|
Intra-Cellular Therapies Files US Application For Expanded Use Of Lumateperone In Bipolar Settings
- Intra-Cellular Therapies Inc (NASDAQ: ITCI) submits CAPLYTA (lumateperone) supplemental marketing application to the FDA to treat depressive episodes associated with bipolar I or II disorder in adults. The application seeks approval for two indications of CAPLYTA; as monotherapy and as adjunctive therapy with lithium or valproate.
- 02/22/2021
|
CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research
- Patients with stable symptoms of schizophrenia were switched from previous antipsychotic medications with no dose titration to CAPLYTA 42 mg for a 6-week treatment duration, then switched back to previous or another approved antipsychotic.
- 01/21/2021
|
Do Options Traders Know Something About Intra-Cellular Therapies (ITCI) Stock We Don't?
- Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
- 01/06/2021
|
Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference
- NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 9:10 am ET.
- 01/05/2021
|
Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder
- The Company continues expansion of its lumateperone programs with the advancement of a Long-Acting injectable formulation into clinical trials.
- 12/29/2020
|
Intra-Cellular Therapies: Another Growth Cycle Approaching
- After a magnificent performance last year with Caplyta approval for schizophrenia, Intra-Cellular stocks gave up some gains. And it's been trading in cyclical growth spurts of gives and takes. Investors are eyeing Caplyta sales to ascertain that the drug has strong sales prospects. Moreover, they want to see additional catalysts materialize.
- 12/04/2020
|
2 Underrated Biotech Stocks to Buy Now
- These two biotech companies are safe bargains in today's volatile market.
- 12/01/2020
|
Intra-Cellular Therapies to Present at the Evercore ISI 3rd Annual HealthCONx Conference
- NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Wednesday, December 2, 2020 at 9:15am ET.
- 11/30/2020
|
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q3 2020 Results - Earnings Call Transcript
- Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q3 2020 Results - Earnings Call Transcript
- 11/09/2020
|
Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
- P ositive topline results reported from Study ‘402, a Phase 3 Study evaluating lumateperone as an adjunctive treatment to lithium or valproate in patients with bipolar depression.
- 11/09/2020
|
Got $1,000? You Could Double Your Money by Investing in These 2 Biotechs
- Innovation might be worth the high risk up front investment.
- 11/07/2020
|
Intra-Cellular Therapies to Host Third Quarter 2020 Financial Results Conference Call and Webcast
- NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Monday, November 9, 2020, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2020.
- 11/04/2020
|
Intra-Cellular Therapies: Navigating Choppy CNS Treatment Waters With Aplomb (NASDAQ:ITCI)
- Intra-Cellular won approval for Schizophrenia treatment Caplyta in Dec 2019 after a protracted review by the FDA.
- 09/30/2020
|
Paediatric Neuropsychiatric Disorders Treatment Market Size, Share Global Development Strategy, Explosive Factors of Revenue by Key Vendors Demand, Future Trends and Industry Growth Research Report
- Sep 30, 2020 (The Expresswire) --
Global Paediatric Neuropsychiatric Disorders Treatment Market Report tracks the major market events including product...
- 09/30/2020
|
Enhanced Healthcare Partners Announces Investment in NeuroPsychiatric Hospitals
- Enhanced Healthcare Partners (“EHP”), a leading healthcare-focused private equity firm specializing in middle-market healthcare services businesses, i
- 09/30/2020
|
Notable Insider Buys of the Past Week: Nikola, Transdigm And More
- Insider buying can be an encouraging signal for potential investors when markets are near all-time highs.
One beneficial owner took advantage of secondary offerings at...
- 09/20/2020
|
Intra-Cellular Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
- Intra-Cellular stock jumps as its bipolar trial delivers positive data. Medtronic moves ahead with heart valve disease trial.
- 09/12/2020
|
Intra-Cellular Therapies Inc (ITCI) Q2 2020 Earnings Call Transcript
- Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer, Dr. Andrew Satlin, Executive Vice President and Chief Medical Officer, Mark Neumann, Executive Vice President and Chief Commercial Officer, Larry Hineline, Senior Vice President and Chief Financial Officer, and Michael Halstead, Executive Vice President and General Counsel. As a reminder, during today's call, we will be making certain forward-looking statements.
- 08/10/2020
|
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Misses Revenue Estimates
- Intra-Cellular (ITCI) delivered earnings and revenue surprises of -2.13% and -37.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/10/2020
|
Recap: Intra-Cellular Therapies Q2 Earnings
- Shares of Intra-Cellular Therapies (NASDAQ:ITCI) fell 2% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share decreased 41.18% year over year to ($0.96), which missed the estimate of ($0.91).Revenue of $1,907,000 higher by 0.00% from the same period last year, which missed the estimate of $3,030,000.Guidance Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: Aug 10, 2020View more earnings on ITCITime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/wen7vxuxRecent Stock Performance 52-week high: $43.5652-week low: $6.75Price action over last quarter: Up 7.13%Company Overview Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.See more from Benzinga * Earnings Scheduled For August 10, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/10/2020
|
Intra-Cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
- NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the second quarter ended June 30, 2020, and provided a corporate update.“We have completed our first full quarter of commercial activities, adapting to the unprecedented challenges of the COVID-19 pandemic, and I am encouraged by CAPLYTA’s week over week prescription growth and increasing prescriber base,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “I am pleased with our team’s performance in the current environment, the positive physician response to CAPLYTA and the impact we are making in the lives of patients suffering from schizophrenia. We are also excited about advancements in our pipeline, including the upcoming announcement of results from our Phase 3 clinical trial evaluating lumateperone as an adjunctive treatment in bipolar depression (Study 402) and the continued progress in our other pipeline programs.”CORPORATE UPDATE COMMERCIAL HIGHLIGHTS * CAPLYTA promotional activities for the treatment of schizophrenia in adults commenced the week of March 30, 2020. Our commercial organization quickly adapted to the challenges to the healthcare industry and patient care brought by COVID-19. * Following a successful virtual launch, our neuroscience sales specialists are actively engaging with healthcare providers educating on CAPLYTA. We have been effectively engaging with our prescribing audience through a mix of personal and non-personal promotion including both remote, and more recently, live in-person interactions with our sales team, peer to peer medical education, journal advertising, virtual conferences & product theatre presentations and digital marketing efforts. * CAPLYTA has now achieved formulary coverage for greater than 95% of covered lives in both Medicare Part D and State Medicaid, our two largest channels. We continue to see coverage determination improvements in the commercial payer channel with final coverage expected to be established by the end of this year. * We are launching our new consumer campaign called “Real Progress”. The purpose of the campaign is to educate patients and caregivers about CAPLYTA and to open the dialogue about optimizing care and treatment options. “Real Progress” includes a national direct-to-consumer (or DTC) television advertising campaign and accompanying social media campaign, as well as a partnership with a leading telepsychiatry platform. * Our LYTAlink™ patient access and affordability program is fully operational and performing as planned. The program offerings consist of coverage and reimbursement services, out-of-pocket copay support for commercially insured patients, medication compliance communications, and patient assistance relief specifically for eligible patients without insurance. CLINICAL HIGHLIGHTS * Lumateperone in Bipolar Depression: Study 402, our Phase 3 study evaluating lumateperone as adjunctive therapy in bipolar depression, has completed clinical conduct and we anticipate reporting topline results from this study by mid-September 2020. This global study enrolled patients with major depressive episodes associated with either Bipolar I or Bipolar II disorder, who were randomized (1:1:1) to receive lumateperone 42 mg, 28 mg or placebo once daily for six weeks, while being maintained on lithium or valproate as mood stabilizers. The primary endpoint is change from baseline on the Montgomery–Åsberg Depression Rating Scale (MADRS) total score at week 6. Study 403, a Phase 3 global study evaluating lumateperone 42 mg as monotherapy in the treatment of depression in patients with Bipolar I or Bipolar II disorder, is ongoing. We anticipate reporting top-line results from this study in the second half of 2021. * ITI-214 in Heart Failure: We reported positive results from our Phase 1/2 clinical trial of ITI-214, our phosphodiesterase 1 (PDE1) inhibitor, in patients with chronic systolic heart failure. This study evaluated the hemodynamic profile and safety of single ascending doses of ITI-214. In the study, ITI-214 improved cardiac output both by increasing heart contractility and by decreasing vascular resistance, that is, ITI-214 functions as an inodilator. The improvement in cardiac output was not associated with the development of arrhythmias in patients. Details of these results will be presented at upcoming medical conferences. * Other Clinical Programs: We plan to initiate our lumateperone clinical program in major depressive disorder later this year. In addition, we expect to initiate human testing of our lumateperone long-acting injectable program later this year. We also expect to initiate early stage clinical studies for ITI-333, our novel, oral modulator of mu opioid and serotonin receptors for the treatment of opioid and other substance use disorders, pain, and mood disorders.Selected Second Quarter 2020 Financial Results The Company recorded net product sales of CAPLYTA for the second quarter of 2020 of approximately $1.9 million. No net product sales were reported for the comparable period of 2019.The Company reported a net loss of $63.7 million, or $0.96 per share (basic and diluted), for the second quarter of 2020 compared to a net loss of $37.4 million, or $0.68 per share (basic and diluted), for the second quarter of 2019.Research and development (R&D) expenses for the second quarter of 2020 were $25.2 million, compared to $23.7 million for the second quarter of 2019. The $1.5 million increase is primarily due to an increase of approximately $9.2 million of lumateperone clinical costs and an increase of approximately $0.6 million in stock compensation expense and overhead expenses and is offset by a decrease of approximately $5.3 million of manufacturing costs, and a decrease of approximately $3.0 million for non-clinical related efforts.Selling, general and administrative (SG&A) expenses were $41.4 million for the second quarter of 2020, compared to $15.4 million for the same period in 2019. The increase of $26.0 million is due to an increase of $20.6 million for selling related costs and an increase of $5.4 million for general and administrative costs. The increase in selling related costs is due primarily to hiring a sales force, resulting in an increase in labor expenses of $15.0 million and commercialization and marketing costs of $5.0 million. The increase in general and administrative costs is due primarily to an increase in labor related expenses of $2.3 million, information technology expenses of $1.5 million, and professional fees of $1.0 million.Cash, cash equivalents, restricted cash and investment securities totaled $409.2 million at June 30, 2020, compared to $224.0 million at December 31, 2019. In January 2020, the Company completed a $295.0 million public offering resulting in net proceeds to the Company of approximately $277.0 million from the sale of 10 million shares of its common stock, after deducting underwriting discounts and commissions and offering expenses paid by the Company. Conference Call and Webcast DetailsThe Company will host a live conference call and webcast today at 8:30 AM Eastern Time to discuss the Company's financial results and provide a corporate update. The live webcast and subsequent replay may be accessed by visiting the Company's website at www.intracellulartherapies.com. Please connect to the Company's website at least 5-10 minutes prior to the live webcast to ensure adequate time for any necessary software download. Alternatively, please call 1-(844) 835-6563 (U.S.) or 1-(970) 315-3916 (international) to listen to the live conference call. The conference ID number for the live call is 1574586. Please dial in approximately 10 minutes prior to the call.CAPLYTA™ (lumateperone) is indicated for the treatment of schizophrenia in adults. CAPLYTA is available in 42 mg capsules.Important Safety InformationBoxed Warning: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis.Contraindications: CAPLYTA is contraindicated in patients with known hypersensitivity to lumateperone or any components of CAPLYTA. Reactions have included pruritus, rash (e.g. allergic dermatitis, papular rash, and generalized rash), and urticaria. Warnings & Precautions: Antipsychotic drugs have been reported to cause: * Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis, including stroke and transient ischemic attack. See Boxed Warning above. * Neuroleptic Malignant Syndrome (NMS), which is a potentially fatal reaction. Signs and symptoms include: high fever, stiff muscles, confusion, changes in breathing, heart rate, and blood pressure, elevated creatinine phosphokinase, myoglobinuria (and/or rhabdomyolysis), and acute renal failure. Patients who experience signs and symptoms of NMS should immediately contact their doctor or go to the emergency room. * Tardive Dyskinesia, a syndrome of uncontrolled body movements in the face, tongue, or other body parts, which may increase with duration of treatment and total cumulative dose. TD may not go away, even if CAPLYTA is discontinued. It can also occur after CAPLYTA is discontinued. * Metabolic Changes, including hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain. Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma or death, has been reported in patients treated with antipsychotics.
- 08/10/2020
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
- Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
- 08/09/2020
|
Did Hedge Funds Make The Right Call On Intra-Cellular Therapies Inc (ITCI)?
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- 08/04/2020
|
Intra-Cellular Therapies to Host Second Quarter 2020 Financial Results Conference Call and Webcast
- NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Monday, August 10, 2020, to provide a corporate update and discuss details of the Company's financial results for the quarter ended June 30, 2020. To access the live conference call via phone, dial 1-(844) 835-6563. The international dial-in number is 1-(970) 315-3916. The conference ID number for the live call is 1574586.The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.About Intra-Cellular TherapiesIntra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.CONTACT:Intra-Cellular Therapies, Inc. Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations 646-440-9333Burns McClellan, Inc. Lisa Burns jgrimaldi@burnsmc.com 212-213-0006
- 08/04/2020
|
Goa launches online ITI admissions, student data management system
- The new online admission process will allow pre-filing of trade preferences, instead of waiting on the day of the rounds, as done earlier.
- 08/04/2020
|
Iteris Reports 11% Revenue Growth Year Over Year with Significant Increases in GAAP Net Income and Adjusted EBITDA for Fiscal First Quarter
- Iteris today reported financial results for its fiscal first quarter 2021 ended June 30, 2020.
- 08/04/2020
|
Iteris (ITI) Scheduled to Post Earnings on Tuesday
- Iteris (NASDAQ:ITI) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, August 4th. Analysts expect Iteris to post earnings of ($0.04) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link. Iteris (NASDAQ:ITI) last issued its […]
- 08/03/2020
|
ONGC Recruitment 2020: Application process for 4,182 Apprentice posts begins at ongcindia.com; freshers apply
- ONGC Recruitment 2020: Oil and Natural Gas Corporation Limited, ONGC has invited online applications for 4182 apprentice vacancies on the official ONGC Apprentices on its official website. Eligible candidates can apply online through the official site of ONGC at ongcindia.com. The last date to apply for the post is till August 17, 2020.
- 07/30/2020
|
Here's Why We're Not Too Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
- We can readily understand why investors are attracted to unprofitable companies. For example, Intra-Cellular Therapies...
- 07/28/2020
|
Automakers turn to technical training institutes to hire manpower
- Maruti Suzuki India Ltd has asked its vendors to recruit additional staff to have enough manpower to ramp up production for the coming months.Hyundai Motor plans to hire 1,800 staffers, mainly polytechnic and ITI diploma holders, at its Chennai plant as it resumes the third shift
- 07/27/2020
|
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
- Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
- 07/26/2020
|
FSCS opens up claims service for SVS Securities' clients willing to make further claims - FinanceFeeds
- The UK Financial Services Compensation Scheme would like to begin looking at other issues that have arisen following the failure of SVS.
- 07/24/2020
|
ITI Capital appoints Steve Kelso as head of capital markets
- ITI Capital, the EM-focused multi-asset Prime Broker for institutional investors and private clients, has today announced appointment of Steve Kelso
- 07/22/2020
|
American IT body says digital services tax aims only non-Indian e-commerce firms with widest ramifications
- The global tech trade association said that the tax imposed by India has the widest ramifications compared to the nine other countries.
- 07/18/2020
|
Geode Capital Management LLC Has $1.80 Million Stock Position in Iteris Inc (NASDAQ:ITI)
- Geode Capital Management LLC lifted its stake in Iteris Inc (NASDAQ:ITI) by 8.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 561,261 shares of the technology company’s stock after acquiring an additional 44,517 shares during the period. Geode Capital […]
- 07/15/2020
|
ISTH 2020虛擬大會將呈報的新資料展示Octapharma對出血性疾病患者的承諾
- (美國商業資訊)--Octapharma今天宣布，其血液科產品陣容的新研究結果將在2020年7月12–14日召開的國際血栓形成和止血學會(ISTH)虛擬大會上呈報。 NuProtect研究(NCT01712438)調查Nuwiq® (simoctocog alfa)在108例既往未曾治療的A型血友病
- 07/14/2020
|
Comunicado do Business Wire :Octapharma
- A Octapharma anunciou hoje que novas descobertas de pesquisas de seu portf
- 07/13/2020
|
New Data to Be Presented at the ISTH 2020 Virtual Congress Demonstrating Octapharma’s Commitment to Patients With Bleeding Disorders
- Octapharma announced today that new research findings from its haematology portfolio will be presented at the upcoming International Society on Thromb
- 07/13/2020
|
Opinion | A plan for us to create a globally competitive industrial sector
- Five ideas that are not difficult to implement and can form part of a focused long-term strategy
- 07/12/2020
|
Iteris Inc (NASDAQ:ITI) Shares Bought by Alliancebernstein L.P.
- Alliancebernstein L.P. grew its position in shares of Iteris Inc (NASDAQ:ITI) by 45.6% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,500 shares of the technology company’s stock after purchasing an additional 8,300 shares during the period. Alliancebernstein L.P. owned approximately […]
- 07/12/2020
|
Do Options Traders Know Something About Intra-Cellular Therapies (ITCI) Stock We Don't?
- Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
- 07/07/2020
|
Sarkari Naukri! ALIMCO announced 74 ITI Apprentices Vacancies; Last Date to apply 20 July
- ALIMCO is inviting applications for the posts of 74 ITI Apprentices from ITI pass candidates. Interested applicants can apply online before 20 July 2020 at official website alimco.in/. Interestingly, the selected candidates will be paid as per Apprenticeship ACT – 1961.
- 07/07/2020
|
Intra-Cellular Therapies (NASDAQ:ITCI) Downgraded to “Hold” at BidaskClub
- Intra-Cellular Therapies (NASDAQ:ITCI) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, BidAskClub reports. Other equities analysts have also recently issued research reports about the company. Zacks Investment Research cut Intra-Cellular Therapies from a “buy” rating to a […]
- 07/07/2020
|
ITI Ltd up; telecom PSUs barred from using Chinese equipment for 4G upgrade
- After a violent face-off between Chinese and Indian troops in Galwan Valley, Ladakh, last month, the DoT had asked BSNL and MTNL not to use Chinese equipment for upgradation of the 4G network
- 07/06/2020
|
Tech Mahindra to bid for BSNL 4G tender, says Indian companies have capabilities
- Tech Mahindra and ITI are also looking to tap the global market with their upgraded 4G and 5G network equipment based on the success with the BSNL tender and implement the solution.
- 07/05/2020
|
BNP Paribas Arbitrage SA Acquires 6,899 Shares of Iteris Inc (NASDAQ:ITI)
- BNP Paribas Arbitrage SA increased its holdings in shares of Iteris Inc (NASDAQ:ITI) by 125.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,406 shares of the technology company’s stock after acquiring an additional 6,899 shares during the quarter. BNP Paribas Arbitrage […]
- 07/03/2020
|
How ‘Lockdown 1 meal a day’ fed a taluka of 130 villages with a dedicated Covid centre
- PUNE Until June, 130 villages in Velhe taluka, a population of at least 50,000 citizens were facing the Covid-19 pandemic with no dedicated Covid care centre for tests or...
- 07/02/2020
|
The women desperate to bag a boyfriend before the second wave – dressing up for the supermarket and flirting in the park
- SINGLE women across the UK have endured a tough few months, being forced into a sexless lockdown while hearing couples brag about lunchtime quickies and romantic dates at home. And with a second wa…
- 07/02/2020
|
Vivek Oberoi Will Cast New Talent In Next Production Rosie
- "Always tried to support talent so launching something close to my heart!" wrote Vivek Oberoi
- 07/02/2020
|
Vivek Oberoi to produce horror franchise Rosie, promises to ‘make way for new talent’
- Vivek Oberoi has said with every installment of Rosie- The Saffron Chapter, he will launch a new face in Bollywood.
- 07/02/2020
|
Vivek Oberoi announces second production Rosie The Saffron Chapter: Will cast new talent without bias
- Vivek Oberoi announced his second film as a producer titled Rosie. The horror-thriller will be directed by Vishal Mishra.
- 07/02/2020
|
Rosie The Saffron Chapter poster: Vivek Oberoi launches horror franchise, to introduce a new talent in every sequel
- Vivek Oberoi will co-produce Rosie: The Saffron Chapter which will revolve around the mysterious disappearance of a call centre employee.
- 07/02/2020
|
Thrivent Financial for Lutherans Makes New Investment in Intra-Cellular Therapies Inc (NASDAQ:ITCI)
- Thrivent Financial for Lutherans bought a new stake in Intra-Cellular Therapies Inc (NASDAQ:ITCI) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,451 shares of the biopharmaceutical company’s stock, valued at approximately $161,000. Other institutional investors also recently added to or reduced their stakes […]
- 07/02/2020
|
Pandemic slows down placements
- HIRING AMID FIRING Amid uncertainty in the academic calendar of higher educational institutions and downsizing of industry in the region due to the Covid-19 pandemic, campus placements have taken a hit
- 07/01/2020
|
Analysts Offer Insights on Healthcare Companies: Catasys (NASDAQ: CATS), Akero Therapeutics (NASDAQ: AKRO) and Zynerba Pharmaceuticals (NASDAQ: ZYNE) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Catasys (CATS
- 07/01/2020
|
Vivek Oberoi turns producer with Iti, film to go on floors in October
- Vivek Oberoi announced his first film as a producer titled Iti. The murder mystery will be directed by Vishal Mishra.
- 07/01/2020
|
Sushmita Sen's brother Rajeev Sen set for Bollywood debut
- Sushmita Sens brother Rajeev Sen will make his Bollywood debut with 'Iti: Can You Solve Your Own Murder?' He says he always had a hidden desire to express his creative side.
- 07/01/2020
|
A Director at Iteris (NASDAQ: ITI) is Buying Shares - Markets
- Yesterday, a Director at Iteris (ITI – Research Report), Tom Thomas, bought shares of ITI for $48.7K. Following this transaction
- 07/01/2020
|
From Ludo King, MagTapp, to Mitron and Betterhalf.ai, here are some China-free Indian apps
- India's decision to ban 59 Chinese apps has been hailed as a 'revolution' for homegrown tech companies. Here are some Indian apps by companies that have no Chinese investments.
- 06/30/2020
|
iTicoin (ITI) Reaches Market Capitalization of $35,082.31
- iTicoin (CURRENCY:ITI) traded up 0.2% against the US dollar during the 1 day period ending at 11:00 AM ET on June 30th. iTicoin has a total market cap of $35,082.31 and $249.00 worth of iTicoin was traded on exchanges in the last 24 hours. During the last week, iTicoin has traded 6.2% lower against the […]
- 06/30/2020
|
Iti first poster: Vivek Oberoi to co-produce murder mystery, cast announcement soon
- Vivek Oberoi has shared the poster of his upcoming production, Iti. The cast of the film is yet to be announced.
- 06/30/2020
|
Fuel price hike: Congress activists hold agitation across Punjab
- Leaders and workers manually pulled tractors to underscore the impact of the rise in fuel prices on farmers
- 06/29/2020
|
Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I/II Study in Patients with Heart Failure
- Study demonstrated inhibiting phosphodiesterase-1 with ITI-214 in patients with heart failure improved cardiac function by enhancing cardiac contractility and dilating systemic arteries without inducing abnormal heart rhythms. NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (ITCI) today announced topline results from Study ITI-214-104, a Phase I/II translational study of single ascending doses of ITI-214, a novel, selective phosphodiesterase-1 (PDE1) inhibitor, in patients with chronic systolic heart failure with reduced ejection fraction (HFrEF). ITI-214 is the first PDE1 inhibitor to be tested in patients with HFrEF.
- 06/29/2020
|
Plants open, workers line up, Manesar auto hub starts moving
- “More than 100 men have joined already. My hope is that even if they keep me as a temporary employee, they should not ask me to leave soon,” says Deepak Kumar, from Bhiwani.
- 06/28/2020
|
Govt order to companies for stocking up 2 months' LPG supply in Kashmir sparks speculations
- Describing the order as a "matter most urgent", the director asked the oil marketing companies to make adequate stocks of LPG which can last up to two months both at bottling plants as well as godowns.
- 06/28/2020
|
Govt order asks OMCs to stock up LPG supply in Kashmir, sparks speculations
- Describing the order as a 'matter most urgent', the director asked the oil marketing companies to make adequate stocks of LPG
- 06/28/2020
|
Order for increasing LPG stock in Kashmir Valley issued in view of monsoon: Official
|
Govt order to companies for stocking up 2 months’ LPG supply in Kashmir sparks speculation
- Though similar exercises are common in winter months in view of frequent disruptions on the Srinagar-Jammu National Highway, such huge stocking does not usually take place in summers.
- 06/28/2020
|
Govt order to companies for stocking up 2 months' LPG supply in Kashmir sparks speculations
- A government order asking oil marketing companies to stock up two months' supply of LPG cylinders in Kashmir Valley has sparked speculations, especially in the wake of the LAC face-off, with NC leader Omar Abdullah questioning the need for such a move.
- 06/28/2020
|
45 home guards quarantined in Uttarakhand after 2 constables test Covid-19 positive
- With these two fresh cases, a total of nine police staff have tested positive for Covid-19 in Uttarakhand.
- 06/28/2020
|
Govt Order to Companies for Stocking up 2 Months' LPG Supply in Kashmir Sparks Speculations
- Former CM Omar Abdullah cited another communique by the Ganderbal district police for making provisions for lodging of central forces and sought an explanation from the government.
- 06/28/2020
|
The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week
- Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development...
- 06/28/2020
|
How masks have become a money-spinner for Haryana government
- State makes earnings of ₹1.86 crore through challans in 17 days alone
- 06/27/2020
|
Punjab govt to honour 148 ITI girls who armed Covid warriors with 2.3 lakh masks
- Readied masks using sewing machines at home; 13 principals will also be acknowledged for motivating the students
- 06/27/2020
|
General Electric : DescriptionAnnual Report of Employee Stock Plans | MarketScreener
|
ITI Ltd ties up with Tech Mahindra for 5G tech
- "The partnership will not only help to reduce dependency on import of Telecom equipment from foreign countries but also address the concerns in building a strategic network for Defense Communication," R M Agarwal, Chairman & Managing Director, ITI Limited said.
- 06/26/2020
|
ITI Ltd Q4 profit drops 47% to ₹36.4 crore
- ITI posted a 47% drop in consolidated profit at ₹36.46 crore for the March quarter as against ₹68.74 crore in the same period a year ago, on account of COVID-19 disrupting the supply chain
- 06/26/2020
|
Tech Mahindra- ITI to make 5G tech in India
- ITI and Tech Mahindra will collaborate to create 'Make in India' stack as part of this MoU for the upcoming 4G & 5G opportunities in India
- 06/26/2020
|
Tripura to start data science, large scale integration courses from current academic session
- Education Minister Ratan Lal Nath told reporters here today that the All Indian Council of Technical Education (AICTE) has approved a proposal for starting M. Tech courses with specialisation in the three novel disciplines at Tripura Institute of Technology
- 06/26/2020
|
Study focuses on driving bacteria to produce potential antibiotic, antiparasitic compounds
- Researchers have developed a method to spur the production of new antibiotic or antiparasitic compounds hiding in the genomes of actinobacteria, which are the source of drugs such as actinomycin and streptomycin and are known to harbour other untapped chemical riches.
- 06/26/2020
|
ITI Ltd Q4 profit drops 47 pc to Rs 36.4 cr
- State-run electronics manufacturing firm ITI Ltd on Friday posted a 47 per cent drop in consolidated profit at Rs 36.46 crore for the March quarter on account of COVID-19 disrupting the supply chain The company had reported a profit of Rs 68.74 crore in the same period a year ago.
- 06/26/2020
|
SGX Nifty up 55 points; here's what changed for market while you were sleeping
- Nifty futures on the Singapore Exchange traded 57.5 points, or 0.56 per cent higher at 10,293.50, in signs that Dalal Street was headed for a positive start on Friday.
- 06/26/2020
|
Stocks in the news: ITC, RIL, Vedanta, Ruchi Soya, Ashok Leyland and Coal India
- Fitch Ratings upgraded RIL's long-term local-currency issuer default rating (IDR) to 'BBB+' from 'BBB',
- 06/26/2020
|
Stocks in news: IRCTC, HAL, Ashok Leyland, CONCOR, Apollo Hospitals, Glenmark Pharma and more
- Stocks to watch today on June 26: HAL, Ashok Leyland, CONCOR, Apollo Hospitals, IRCTC, Glenmark Pharma among others are the top stocks to watch out for in Friday's trading session.
- 06/26/2020
|
IBM rolls out free digital learning platform to reach more job seekers, provide new resources to business owners
- In November 2019, IBM India, in partnership with Directorate General of Training (DGT), Ministry of Skill Development and Entrepreneurship, Government of India, and its implementation partners, made the SkillsBuild online learning platform available to Indian students.
- 06/25/2020
|
Intra-Cellular Therapies (ITCI) Investor Presentation - Slideshow
- The following slide deck was published by Intra-Cellular Therapies, Inc. in conjunction with this event.
- 06/25/2020
|
'Opportunity to Help Country': Hit By Covid-19 Lockdown, Locals Queue Up in Sikkim to Join Army
- The Army's job notification for 600 vacancies mentioned that those physically fit and in the 18-40 age group would be eligible to join as porters for a contract period of 179 days.
- 06/25/2020
|
Intra-Cellular Therapies Target of Unusually Large Options Trading (NASDAQ:ITCI)
- Intra-Cellular Therapies Inc (NASDAQ:ITCI) was the target of some unusual options trading activity on Tuesday. Investors acquired 7,994 put options on the company. This represents an increase of 1,874% compared to the average daily volume of 405 put options. In other Intra-Cellular Therapies news, Director Joel S. Marcus sold 7,297 shares of Intra-Cellular Therapies stock […]
- 06/25/2020
|
India to target import and use of smart power meters from China
- The move is part of a broad economic response to Chinese aggression along the border in Ladakh.EESL’s smart meter programme is aimed at replacing a total of 250 mn conventional meters
- 06/25/2020
|
When you kept doubting the stocks rally, 32 BSE500 stocks doubled wealth in 3 months
- 95% of BSE500 stocks from across sectors have delivered a positive returns since March 24.
- 06/24/2020
|
India’s smart meter programme to shun Chinese manufacturers
- NDA government plans to convert all electricity meters into smart prepaid meters by 2022
- 06/24/2020
|
BNP Paribas Arbitrage SA Increases Stake in Intra-Cellular Therapies Inc (NASDAQ:ITCI)
- BNP Paribas Arbitrage SA raised its stake in shares of Intra-Cellular Therapies Inc (NASDAQ:ITCI) by 173.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,030 shares of the biopharmaceutical company’s stock after buying an additional 10,797 shares during […]
- 06/24/2020
|
Intra-Cellular Therapies (NASDAQ:ITCI) Trading Up 0.4%
- Intra-Cellular Therapies Inc (NASDAQ:ITCI) shares rose 0.4% on Monday . The company traded as high as $25.63 and last traded at $25.41, approximately 46,360 shares changed hands during mid-day trading. A decline of 95% from the average daily volume of 874,394 shares. The stock had previously closed at $25.31. ITCI has been the subject of […]
- 06/24/2020
|
Do Hedge Funds Love Intra-Cellular Therapies Inc (ITCI)?
- In this article you are going to find out whether hedge funds think Intra-Cellular Therapies Inc (NASDAQ:ITCI) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]
- 06/24/2020
|
Replicate Bioscience and Immunomic Therapeutics Form Collaboration to Combat Infectious Diseases and Cancers
- Replicate Bioscience, Inc. (“Replicate”), a privately-held biopharmaceutical company creating novel treatments to prevent drug resistance in cancers,
- 06/24/2020
|
Intra-Cellular (ITCI) Moves to Buy: Rationale Behind the Upgrade
- Intra-Cellular (ITCI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- 06/23/2020
|
Tech CEOs blast Trump’s new immigration order, but experts say it's 'a lot of bark'
- Amazon, Facebook, Google and Twitter were among the well-known tech firms that blasted the policy in the hours after Trump issued it on Monday.
- 06/23/2020
|
ITI Limited : annual earnings release | MarketScreener
|
Tech firms blast Trump's extended H-1B visa restrictions
- The industry argues that limiting skilled workers from overseas will hurt the U.S. recovery.
- 06/23/2020
|
ITI Limited : publication des résultats annuels | Zone bourse
|
Ban on H-1B visas to hit innovation, foreign investment: US corporate sector
- Today's proclamation is a severe and sweeping attempt to restrict legal immigration. Putting up a not welcome' sign for engineers, executives, IT experts, doctors, nurses and other workers won't help our country, it will hold us back, he said.
- 06/23/2020
|
Trump's temporary ban on immigration visas leaves tech industry miffed
- The US press reported that the Trump administration is also weighing several additional changes to legal immigration via regulation
- 06/23/2020
|
'Disappointed; stand with immigrants,' says Sundar Pichai on Trump's H-1B suspension order
- Pichai was, however, not the only one to express his disappointment over the proclamation that temporarily suspends H-1B visas.
- 06/23/2020
|
Ban on H-1B visas to hit innovation, foreign investment: US corporate sector
- “Restrictive changes to our nation’s immigration system will push investment and economic activity abroad, slow growth, and reduce job creation,” said Thomas Donohue, CEO of US Chambers of Commerce soon after President Donald Trump issued a proclamation to suspend issuing of H-1B and other foreign work visas till the end of the current year. “Today’s proclamation is a severe and sweeping attempt to restrict legal immigration.
- 06/23/2020
|
H-1B visa ban to hit innovation, foreign investment: US corporate sector
- The Trump administration should stop trying to create and exploit crises to enact the largest cuts to legal immigration in a century. This is deeply harmful to America, Schultz said
- 06/23/2020
|
Iteris Appoints Anjali Joshi to Its Board of Directors
- Iteris today announced that Anjali Joshi, former vice president of product management at Google, has been appointed to its board of directors.
- 06/23/2020
|
Trump extiende los límites de algunas visas de trabajo hasta 2020
- Los nuevos límites son parte de un esfuerzo concertado para revertir las visas disponibles para las personas en el extranjero como resultado del alto desempleo en Estados Unidos por la pandemia de …
- 06/22/2020
|
China has a 15-year plan to shape the future of tech. But some call it hype
- China Standards 2035 is an ambitious 15-year blueprint that will lay out Beijing's plans to set the global standards for the next-generation of technologies.
- 06/22/2020
|
Meet private school principal in Telangana, forced to sell idli on a cart
- The sweeping economic distress triggered by the Covid pandemic and lockdown has pushed countless out of jobs, set off one of the biggest reverse migrations in recent times and pushed millions of small businesses to the edge.
- 06/20/2020
|
Iteris’ (ITI) Outperform Rating Reiterated at JMP Securities
- Iteris (NASDAQ:ITI)‘s stock had its “outperform” rating reissued by analysts at JMP Securities in a research note issued on Thursday, AnalystRatings.com reports. They presently have a $9.00 target price on the technology company’s stock. JMP Securities’ target price indicates a potential upside of 108.33% from the stock’s previous close. Several other analysts also recently commented […]
- 06/20/2020
|
Tech Mahindra plans to foray into telecom equipment manufacturing
- “They are saying that their equipment has been deployed at some places in Japan but apart from that, no details have been shared with us,” said a source in the DoT.
- 06/20/2020
|
Market Movers: RIL, TaMo soar; VIX slumps; 90 stocks give buy signals
- Here is a lowdown on what happened in Fridays session.
- 06/19/2020
|
Share market update: 59 stocks hit 52-week highs on NSE
- Benchmark NSE Nifty index was trading 46.65 points up at 10138.30.
- 06/19/2020
|
Powergrid Recruitment 2020: 60 vacancies for apprentices on offer, check details
- Interested and eligible candidates can apply for the position online at careers.powergrid.in on or before July 8, 2020.
- 06/19/2020
|
Intra-Cellular Therapies (NASDAQ:ITCI) Downgraded to “Hold” at Zacks Investment Research
- Intra-Cellular Therapies (NASDAQ:ITCI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday, Zacks.com reports. According to Zacks, “Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. […]
- 06/19/2020
|
Ahead of Market: 12 things that will decide stock action on Friday
- A look at what some of the key indicators are suggesting for Fridays market action.
- 06/18/2020
|
Market Movers: BHEL, Coal India come to party; telcos feel AGR pinch; 100 stocks hit 52-week highs
- Here is a lowdown on what happened in Thursdays session.
- 06/18/2020
|
IGL share price closes 5% lower post Q4 earnings
- Indraprastha Gas Ltd (IGL) share price closed lower after the firm announced a 12 per cent rise in March quarter net profit due to higher gas sales. Share price of IGL ended 5.44% to Rs 448 against previous close of Rs 473.90 on BSE. IGL stock has fallen
- 06/18/2020
|
Sarkari Naukri! Assam Police Junior Assistant and Stenographer vacancies announced; all details here
- Assam Police has invited applications for 7 Junior Assistant and Stenographer posts from Graduate candidates interested in a sarkari naukri. Candidates who wish to be a part of Assam Police recruitment process can apply online before 6 July, 2020.
- 06/18/2020
|
PSU stocks in upbeat mood: ITI, BHEL, Coal India rally up to 20%
- Shares of Indian Telephone Industries Limited (ITI) hit an upper circuit of 20 per cent amid reports that the Department of Telecom (DoT) has asked BSNL and MTNL to not use Chinese equipment for 4G upgradation
- 06/18/2020
|
Commercial mining to free coal sector from decades of lockdown: PM Modi
- Says was excluded from competition, there was a big problem of transparency; wants India to aim at becoming world's largest coal exporter
- 06/18/2020
|
ITI Ltd jumps 19% on reports BSNL, MTNL barred from using Chinese 4G equipment
- The stock has rallied 32% in the last two days. Since the beginning of the year, shares have surged 12.6% compared to an 18.2% decline in the Sensex
- 06/18/2020
|
ITI hits 52-wk high as govt bars BSNL, MTNL from using Chinese 4G equipment
- Besides the state-owned telcos, government may ask private players to stay away from such Chinese firms.
- 06/18/2020
|
General Electric : DescriptionPost-Effective Amendment to an S-8 filing | MarketScreener
|
Neurocrine Adds to Pipeline With $2 Billion Takeda Deal
- Biotech gets 7 drugs in partnership, 3 of which are in phase 2 testing Continue reading...
- 06/17/2020
|
Border tensions send Sensex 97 points lower; VIX climbs for 5th day
- Even as frontline indices closed lower, the market breadth tilted in favour of the bulls.
- 06/17/2020
|
Sepoy Ganesh Hansda, 22, killed in Ladakh face-off was on his 1st posting
- Ganesh Hansda, says his brother, was to be transferred but it was delayed due to the coronavirus crisis.
- 06/17/2020
|
Die MOTIVATE-Studie (MOdern Treatment of Inhibitor-positiVe pATiEnts
with haemophilia A) beginnt mit der Rekrutierung von Patienten
- Dr. Carmen Escuriola-Ettingshausen und Dr. Robert Sidonio geben bekannt, dass MOTIVATE (MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A) in den Vereinigten Staaten und Europa zugelassen …
- 06/17/2020
|
3 “Strong Buy” Pharmaceutical Stocks With Major Catalysts Approaching
- Even during economic downturns, one fact remains resolute: pharma stocks represent the ultimate risk/reward plays. Out on Wall Street, the sector has become known for its high volatility. How did it earn this reputation? It comes down to the nature of the industry itself.Unlike companies in other areas of the market, pharma stocks depend less on earnings results, and more on clinical data and regulatory decisions. As the latter determine the trajectory of these stocks, a single piece of good news can act as a catalyst that sends shares skyrocketing.That being said, shares can plummet just as easily should a company publish lackluster data or if approvals don’t come through. For this reason, in-depth due diligence is necessary before pulling the trigger on a name in this sector.Today, we’ll look at three pharma stocks recommended by Sumant Kulkarni, a top-rated analyst from Canaccord. Kulkarni believes these three tickers could be propelled higher by upcoming clinical trial results that could be huge catalysts for each one. Indeed, according to TipRanks’ database, each ticker scores a “Strong Buy” consensus rating from the rest of the Street and boasts substantial upside potential.Zynerba Pharmaceuticals (ZYNE)Focused on developing transdermally-delivered cannabinoid therapeutics, Zynerba Pharmaceuticals wants to improve the lives of patients suffering from neuropsychiatric conditions like Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE). On the heels of its recent positive data readout and more potential catalysts ahead, Kulkarni believes ZYNE's $5.50 share price looks like a steal.On May 27, ZYNE released data from its Phase 2 open-label BRIGHT trial studying Zygel (ZYN002), a transdermal synthetic cannabidiol gel, in ASD. Even though it’s still early, the data indicated that the asset could serve as an add-on treatment to the standard of care for the behavioral symptoms associated with the condition.Expounding on this, Kulkarni noted, “Specifically, Zygel ‘hit’ on all five sub-scales of the Aberrant Behavior Checklist - Community (ABC-C), and also on the Parent-Rated Anxiety Scale - ASD (PRAS-ASD), while retaining the relatively-benign safety/tolerability profile seen so far.” While certainly promising, focus remains primarily on the data readout for the double-blind, placebo-controlled, CONNECT-FX pivotal trial evaluating Zygel in FXS, which is slated for later this month. “Our view is there is limited read-through from today's ASD data to FXS, but we are encouraged Zygel appears to have activity on scales associated with social parameters. Our stock thesis is unchanged in that FXS has no approved products and trial data remain difficult to call, but we believe ZYNE presents significant opportunity for risk-tolerant investors going into the FXS data set,” Kulkarni commented. If that wasn’t enough, Kulkarni points to several other possible catalysts on the horizon. The verdict from ZYNE’s discussions with the FDA regarding Zygel’s DEE pivotal program is set to come in the next few weeks, with top-line results from the Phase 2 open-label INSPIRE study for Zygel in 22q coming the following quarter.To this end, Kulkarni rates ZYNE a Buy along with an $18 price target. This target implies shares could more than double in the next year. (To watch Kulkarni’s track record, click here) Like Kulkarni, other analysts also take a bullish approach. ZYNE’s Strong Buy consensus rating breaks down into 6 Buys and zero Holds or Sells. Given the $19.17 average price target, the upside potential lands at 249%. (See Zynerba stock analysis on TipRanks)BioXcel Therapeutics (BTAI)Next up we have BioXcel Therapeutics, which uses artificial intelligence (AI) to develop cutting-edge medicines across neuroscience and immuno-oncology. With two major potential catalysts in the near-term, it’s no wonder Wall Street focus has locked in on this name.On June 11, the company revealed that the first patient had been enrolled in RELEASE, its Phase 1b/2 trial assessing the use of BXCL501, a sublingual dexmedetomidine film, in treating opioid withdrawal symptoms.Weighing in on the implications of this development, Kulkarni said, “This on-time start means BXCL501 will move into a sub-chronic dosing setting vs. acute/rescue therapy for agitation where it is farther along in development. This move also ties into BTAI's strategy to build a broader/leading franchise around agitation, which is an approach that we continue to view as smart. We also remain impressed by management's ability to hit stated timelines, and look forward to RELEASE top-line data in 1Q21.”Speaking to the opportunity in this indication, there’s already a significant unmet need, and COVID-19 could potentially make the situation worse for many patients. As a result, Kulkarni projects a 2023 launch and unadjusted peak sales of $472 million in 2030.However, before this, data on the candidate’s use in treating agitation caused by other conditions is expected. Kulkarni is looking forward to the data readout for the Phase 3 SERENITY trial of BXCL501 in agitation in schizophrenia and bipolar disorder this July as well as the results from the Phase 1b/2 TRANQUILITY trial in dementia-induced agitation in mid-2020.Calling the above readouts “two key catalysts”, Kulkarni noted, “We continue to believe SERENITY data will come before TRANQUILITY, and like the risk-reward for the stock going into these events based on solid Phase 1b/2 data in schizophrenia, and proof-of-concept data in dementia.” The analyst added, “We model a probability of approval estimate of 75% for agitation in schizophrenia/bipolar disorder and our 2030E peak unadjusted sales are $313 million. We model 65% probability of approval in agitation in dementia, and our 2030E unadjusted peak sales are $584 million.”All of the above combined with other possible catalysts involving BXCL501 and BTAI’s other candidate, BXCL701, slated for 2H20 prompted Kulkarni to keep a Buy recommendation and $71 price target on the stock. Should the target be met, a twelve-month gain of 34% could be in store.All in all, other analysts are on the same page. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Based on the $89 average price target, which is more aggressive than Kulkarni’s, the upside potential comes in at 68%. (See BioXcel stock analysis on TipRanks)Intra-Cellular Therapies (ITCI)Founded on Nobel-prize winning research that uncovered how therapies impact the inner-workings of cells in the body, Intra-Cellular Therapies hopes to address the unmet needs of patients battling complex psychiatric and neurologic diseases. Ahead of an important possible catalyst, Kulkarni thinks ITCI is “significantly undervalued”.It should be noted that its most recent quarter saw the company achieve a major milestone as its recently-approved Caplyta product, lumateperone, for schizophrenia, was launched. Only on the market since March 23, the asset generated just under $1 million in sales, with Kulkarni calling for $1.1 million. This is impressive as the estimate wasn’t updated after the onset of the COVID-19 pandemic.“Given the current environment, we get the sense that ITCI has been nimble enough to adapt well and has also made good progress with payers... We continue to believe Caplyta could generate meaningful sales in schizophrenia, and at these levels we are BUYERS on this opportunity alone.” Kulkarni explained.Also noteworthy for Kulkarni, though, is the publication of data from the Phase 3 global adjunct trial for lumateperone in bipolar depression, which is set to come in mid-20. Additionally, the analyst points out that ITCI should provide updates regarding its discussions with the FDA on this indication.“That said, we also like the stock going into the mid-20 Phase 3 data for lumateperone in bipolar depression, which represents greater unmet need and is a potentially larger market opportunity with fewer approved products,” Kulkarni stated. The analyst added, “Recall that in 1Q20, ITCI started another monotherapy Phase 3 trial (global) with results expected in 2H21. ITCI, however, expects to send in a supplemental new drug application (sNDA) for bipolar depression in late-2020. With a successful global monotherapy trial and a U.S. trial with mixed results, we believe ITCI has a solid shot at a potential approval in this indication.”The good news didn’t end there. Kulkarni believes that the possible upside drivers extend beyond lumateperone, with Phase 1/2 data for ITI-214 in heart failure expected in the next few weeks.It should come as no surprise, then, that Kulkarni stayed with the bulls. In addition to keeping a Buy rating on the stock, the analyst maintained a $70 price target, which brings the upside potential to 215%.Do other analysts agree with Kulkarni? As it turns out, they do. Only Buy ratings, 3 to be exact, have been received in the last three months, so the consensus rating is a Strong Buy. At $47.67, the average price target indicates 115% upside potential. (See Intra-Cellular stock-price forecast on TipRanks)To find good ideas for pharma stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 06/17/2020
|
AMFI Reclassification: These 7 Stocks Could Be Reclassified Into Largecap Category
- In the forthcoming AMFI reclassification challenged by the coronavirus pandemic and overall grim economic outlook, Edelweiss Alternate Research based on the market-cap has come up the list of stocks that may see a change in category as part of the semi-annual categorization review.
- 06/17/2020
|
RRC NER Result 2020: Eastern Railway announces result for this recruitment; Check name here
- RRC North Eastern Railway Result 2020: The Railway Recruitment Cell of the North Eastern Railway has announced results for recruitment for apprenticeship. The results are related to the Apprentice Training Notification 2019-20
- 06/16/2020
|
Railway Recruitment 2020: Get job as apprentice! Big opportunity for 10th class pass; 196 positions announced for these trades - steno to electrician
- Railway Recruitment 2020: North Central Railway (NCR), Wagon Repair Workshop, Jhansi has invited applications for apprenticeship on its official website. In all, 196 positions have been advertised in seven trades respectively according to the official notification
- 06/16/2020
|
RRC NER Gorakhpur apprentice result 2020 announced! Check full list of candidates selected for DV round at ner.indianrailways.gov.in
- RRC NER Apprentice Result 2020: The Railway Recruitment Cell (RRC), North Eastern Railway (NER) has announced the results for recruitment for Apprentice Training Notification 2019-20.
- 06/16/2020
|
Qué implica que Trump haya relajado el veto a Huawei: las empresas estadounidenses podrán colaborar con ellos en el desarrollo del 5G
- Estados Unidos ha decidido relajar el veto a Huawei para el despliegue de redes 5G debido a que considera que esto les puede ayudar a convertirse en líderes.
- 06/16/2020
|
U.S. firms can work with Huawei on 5G and other standards. Here's what it means
- A change in rule by the U.S. Department of Commerce is significant because it means American firms will be able to have a seat at the table in the formation of so-called standards, which are critical to how technologies work.
- 06/16/2020
|
U.S. Drafts Rule to Allow Huawei and American Companies to Work Together on 5G Standards
- They're also free to work with other US.
- 06/16/2020
|
Iteris Selected by Digital Traffic Systems, Inc. to Deploy ITS Asset Management System for Georgia Department of Transportation
- Iteris is one of the core members of the DTS team that has been awarded an IDIQ contract for statewide ITS maintenance by the Georgia DOT.
- 06/16/2020
|
Microsoft, Facebook Among Tech Giants Called In For PDP Bill Feedback
- The joint committee on personal data protection bill has sought Facebook, Microsoft, ASSOCHAM and NASSCOM’s views on the proposed legislation.
- 06/15/2020
|
Covid crisis underlines urgency of more inclusive employment, employability and education
- Education reforms are an endeavour of profound optimism but have been stifled by purists, vested interests, and regulators. It is illogical to deny the poorna swaraj that comes with the Institutes of Eminence tag to Ashoka University and Ahmedabad University or pursue regulation-driven standardisation for our 993 universities.
- 06/15/2020
|
La Junta aprobará el martes el Plan AIRE, dotado de 165 millones para la creación de unos 19.000 empleos
- Este nuevo plan tendrán una duración de entre seis y ocho meses para que los ayuntamientos puedan sacar adelante distintos proyectos de recuperación tras la crisis sanitaria
- 06/14/2020
|
Non immigrant like H1B visa pivotal to Post Covid 19 recovery: US tech giants to Trump
- The Wall Street Journal reported late last week that the US government is considering suspending a number of employment visas including the H-1B, in view of the massive unemployment in America due to the coronavirus pandemic. Indians are the largest beneficiaries of H-1B visas, receiving about two-thirds of the 85,000 new visas issued each year.
- 06/14/2020
|
HPSEBL Recruitment 2020: Himachal Electricity Board invites application for various positions – all detail here
- The minimum age of the applicant should be 18 years while the upper age limit has been capped at 30 years, as on April 01, 2020.
- 06/14/2020
|
1,892 vacancies for Class 10 pass: HPSEB begins hiring, here's how to apply
- The Himachal Pradesh State Electricity Board Limited (HPSEB) has invited all the interested candidates for Junior T/Mate and Junior Helper (Sub-Station) vacancies.
- 06/14/2020
|
HPSEBL recruitment 2020: Apply for 1892 vacancies for 10th pass
- HPSEBL recruitment 2020: The application process is on and the last date to apply is July 20, 5 pm.
- 06/14/2020
|
Govt Industrial Training Institute in Ludhiana to organise virtual job fair
- Virtual interviews will be conducted next week through video-conferencing and currently, candidates have been asked to register online
- 06/13/2020
|
Global Tax Talks Waver as Pandemic Hits Government Coffers | MarketScreener
|
Performance with a purpose: Meet Arjun Mehra, Artistic Director of Improv Comedy Bangalore
- The professional improv company is changing the way we view theatre, providing individuals with essential life long skills, and strengthening communities. They are even offering online courses and workshops amidst these times of social distancing.
- 06/13/2020
|
US technology firms to be impacted by possible Trump move to ban H-1B visas
- US firms have been the key beneficiaries of the H-1B visa in recent years - seven of the top 10 in fiscal 19 were US headquartered tech firms. Indian companies meanwhile have worked at localising their talent mix in the US, reducing the number of H-1B visas they apply for each year.
- 06/12/2020
|
Dhanuka Agritech share price up 117% since March, might have more upside potential; check target price
- Having surged 117% since March last week, Dhanuka Agritech shares still have some steam left in them. With favourable sector outlook, this agri-inputs stock might just as well climb another 30% from current levels
- 06/12/2020
|
Transfer of SVS Securities' client assets and money to ITI Capital gets completed - FinanceFeeds
- Clients are expected to have access to their client money and client assets from July 23, 2020.
- 06/12/2020
|
Analysts Offer Insights on Healthcare Companies: CytoDyn (Other OTC: CYDY), Bioxcel Therapeutics (NASDAQ: BTAI) and SLANG Worldwide (Other OTC: SLGWF) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CytoDyn (CYDY
- 06/12/2020
|
SVS Securities Client Assets and Money Transferred to ITI Capital
- The Administrator’s of SVS Securities said the transfer of the vast majority of client assets and client money has been transferred to ITI Capital.
- 06/12/2020
|
Ahead of Market: 12 things that will decide stock action on Friday
- A look at what some of the key indicators are suggesting for Fridays market action.
- 06/11/2020
|
How Intra-Cellular Therapies (ITCI) Stock Stands Out in a Strong Industry
- Intra-Cellular Therapies (ITCI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 06/11/2020
|
Analysts Offer Insights on Technology Companies: Iteris (NASDAQ: ITI), Quantum (NASDAQ: QMCO) and OptimizeRx (NASDAQ: OPRX) - Markets
- There’s a lot to be optimistic about in the Technology sector as 3 analysts just weighed in on Iteris (ITI
- 06/10/2020
|
Iteris (ITI) Gets a Buy Rating from Northland Securities - Markets
- In a report released today, Michael Latimore from Northland Securities maintained a Buy rating on Iteris (ITI – Research Report),
- 06/10/2020
|
La Casa Blanca prepara nuevos límites a la inmigración, con el coronavirus como argumento
- El Gobierno de Donald Trump se prepara para implementar otro conjunto de restricciones a la inmigración legal, citando el impacto de la pandemia de coronavirus, incluso cuando defiende la reapertur…
- 06/10/2020
|
National Fertilizers Ltd, ITI partner to give thrust to Skill India initiative
- The Nangal plant of the company in Punjab has signed a Memorandum of Understanding (MoU) with ITI, Nangal to train youth in 12 trades.
- 06/10/2020
|
Intra-Cellular Therapies Inc (NASDAQ:ITCI) Stock Holdings Lifted by Bank of New York Mellon Corp
- Bank of New York Mellon Corp increased its position in shares of Intra-Cellular Therapies Inc (NASDAQ:ITCI) by 22.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 232,027 shares of the biopharmaceutical company’s stock after acquiring an additional 43,146 shares during the […]
- 06/10/2020
|
Iteris, Inc., (ITI) CEO Joe Bergera on Q4 2020 Results - Earnings Call Transcript
- Iteris, Inc., (NASDAQ:ITI) Q4 2020 Earnings Conference Call June 9, 2020 16:30 ET Corporate Participants Jim Byers - MKR Investor Relations Joe Bergera - Presid
- 06/10/2020
|
Stop the world I wanna get off! - CityAM
- The amazing accomplishments I described in my last edition seem a distant memory with what has been a horrific week
- 06/09/2020
|
Hemophilia Treatment Market 2020 Industry Research, Share, Trend, Global Industry Size, Future Analysis, Regional Outlook to 2025
- Jun 09, 2020 (Market Insight Reports) --
Latest research report on 'Hemophilia Treatment Market' delivers a comprehensive study on current market trends. The...
- 06/09/2020
|
Iteris Reports 18% Revenue Growth Year Over Year in Fiscal Fourth Quarter
- Iteris today reported financial results for its fiscal fourth quarter and full year ended March 31, 2020.
- 06/09/2020
|
ITI Berhampur develops UV shoe sole sanitizer
- Odisha's ITI Berhampur has developed India's first ultraviolet-C (UV) sole sanitizer machine for the disinfection of shoes. It was launched by Subroto Bagchi, Chairman Odisha Skill Development Authority, during a webinar on Monday.
- 06/08/2020
|
Collapsed wealth firm sells client book
- After entering administration in August 2019 #administration #clients #dfm
- 06/08/2020
|
Man kills father to get govt job on compassionate grounds
- An unemployed man has murdered his 58-year-old father by throttling to get a government job on compassionate grounds in Kothur village in India.
- 06/07/2020
|
Can Aatmanirbhar Bharat Abhiyaan Help India’s Solar Manufacturing Sector?
- Despite making significant progress in solar power generation since 2014, India’s domestic solar equipment manufacturing industry has not been able to capitalise on the opportunity.
- 06/06/2020
|
Implied Volatility Surging for Intra-Cellular Therapies (ITCI) Stock Options
- Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
- 06/04/2020
|
Assets and money of SVS Securities' clients to transfer to ITI Capital - FinanceFeeds
- The Joint Special Administrators of SVS Securities have appointed ITI Capital Limited as the single regulated broker to whom the client assets and money will be transferred.
- 06/04/2020
|
Iteris Awarded $1 Million Contract by City of Round Rock for Smart Mobility Initiative
- Iteris today announced that it has been awarded a $1M contract by Round Rock, Texas for mobility intelligence solutions and video detection updates.
- 06/03/2020
|
Bihar village struggles to adapt to online classes
- Nearly all the villagers grow vegetables in Chhapki, which has a population of around 1,300 and nearly 400 school-going children.
- 06/02/2020
|
Tecnología para predecir rebrotes del Covid-19 a través de las aguas residuales
- La empresa Facsa de ciclo integral del agua está desarrollando un proyecto integral de investigación sobre SARS-CoV-2 que persigue detectar y cuantificar el material genético del v
- 05/27/2020
|
Intra-Cellular Therapies' Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Intra-Cellular Therapies
- 05/26/2020
|
‘Hockey meri te is desh di jaan hai’
- The Indian Express recounts its encounters with the legend
- 05/26/2020
|
Stocks to watch: Avenue Supermarts, Bharti Airtel, IDFC First Bk, HDFC, ITC
- Here's a look at the stocks that may trade actively in today's trading session
- 05/26/2020
|
Aparece la cabeza de una escultura romana en Cástulo mientras se anuncian nuevas inversiones para consolidar el yacimiento arqueológico
- Cástulo, una de las diez ciudades iberorromanas más importantes de la Antigüedad en la península ibérica, es una extraordinaria fuente de hallazgos. La última gran pieza en desente
- 05/25/2020
|
Tricity buzz: HT Chandigarh reporters’ tracker on all those making, or faking, news amid coronavirus lockdown
- Chandigarh health dept keeps journalists guessing; #Main Bhi Chandigarh Police campaign on course; what went wrong at Bapu Dham colony; and more...
- 05/16/2020
|
Amia Capital LLP Buys Intra-Cellular Therapies Inc, Arvinas Inc, Scholar Rock Holding Corp, ...
|
Intra-Cellular Therapies to Present at the 2020 RBC Capital Markets Global Healthcare Conference
- NEW YORK, May 14, 2020 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central.
- 05/14/2020
|
Stocks in focus: Financials, power, realty shares, Maruti, Infosys, Biocon
- Here's a look at the top stocks that may trade actively in today's trading session
- 05/14/2020
|
Intra-Cellular Therapies to Present at the —…—… RBC Capital Markets Global Healthcare ...
|
Intra-Cellular Therapies to Host Virtual Annual Meeting of Stockholders
- Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will hold its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) virtually due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of meeting participants. Stockholders will not be able to attend the Annual Meeting in person, however, stockholders of record and registered beneficial owners as of the close of business on April 6, 2020, will be able to vote and ask questions during the meeting through the online platform. Stockholders can attend the meeting by accessing www.meetingcenter.io/238568156 and entering the 15-digit control number found on their proxy card, voting instruction form, notice of internet availability of proxy materials, or email previously received.
- 05/13/2020
|
Intra-Cellular Therapies, Inc. (ITCI) CEO Dr. Sharon Mates on Q1 2020 Results - Earnings Call Transcript
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2020 Results Conference Call May 07, 2020 08:30 AM ET Company Participants Dr. Juan Sanchez - VP, Corporate Comm
- 05/10/2020
|
Coronavirus lockdown: Poor internet connectivity, limited resources not a deterrent for these ITI students
- Some students sit on the rooftops, others take shelter under water tanks to beat the internet connectivity issues and sun rays, and attend their online classes on daily basis
- 05/10/2020
|
Saifullah Mir aka Ghazi Haider, 26, is Hizbul’s new face of terror in Kashmir
- Saifullah Mir was inducted into terrorism by Riyaz Naikoo in 2014 and had moved up the Hizbul Mujahideen hierarchy along with his mentor
- 05/10/2020
|
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
- The investors in Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) will be rubbing their hands together with glee today...
- 05/09/2020
|
US Might Work With Huawei On 5G Network After All - Techzim
- Whilst US-China relations are still not patched up it seems the USA is softening its stance on a Huawei-enabled 5G rollout. After repeatedly urging other countries such as the UK, and France not to use Huawei equipment as they roll out their 5G network, the US Department of Commerce is ready to sign off on […]
- 05/09/2020
|
Intra-Cellular Therapies Inc (ITCI) Q1 2020 Earnings Call Transcript
- Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Dr. Andrew Satlin, Executive Vice President and Chief Medical Officer; Mark Neumann, Executive Vice President and Chief Commercial Officer; Larry Hineline, Senior Vice President and Chief Financial Officer; and Michael Halstead, Executive Vice President and General Counsel. As a reminder, during today's call, we will be making certain forward-looking statements.
- 05/08/2020
|
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Misses Revenue Estimates
- Intra-Cellular (ITCI) delivered earnings and revenue surprises of 25.51% and -38.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/07/2020
|
US Considering 5G Collab With China's Huawei | PYMNTS.com
- The U.S. Department of Commerce (DoC) is on the verge of green-lighting collaboration with Huawei Technologies in China to cooperatively develop 5G standards.
- 05/07/2020
|
Intra-Cellular Therapies Q1 EPS $(0.730) Beats $(0.930) Estimate, Sales $1.083M Miss $1.440M Estimate
|
Intra-Cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
- NEW YORK, May 07, 2020 -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for.
- 05/07/2020
|
